Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169506 | SCV000220971 | likely pathogenic | Hyperinsulinemic hypoglycemia, familial, 1 | 2014-12-18 | criteria provided, single submitter | literature only | |
Labcorp Genetics |
RCV000802759 | SCV000942602 | pathogenic | not provided | 2023-03-21 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 2 of the ABCC8 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ABCC8 are known to be pathogenic (PMID: 20685672, 23345197). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 189097). Disruption of this splice site has been observed in individuals with autosomal recessive diffuse hyperinsulinism (PMID: 23275527). This variant is not present in population databases (gnomAD no frequency). |
Clinical Genomics, |
RCV002254156 | SCV002524093 | uncertain significance | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant (rs786204695) in MODY yet. | |
Clinical Genomics, |
RCV002254282 | SCV002524096 | uncertain significance | Transitory neonatal diabetes mellitus | criteria provided, single submitter | research | Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant (rs786204695) in neonatal diabetes yet. | |
Baylor Genetics | RCV004567370 | SCV005057548 | pathogenic | Type 2 diabetes mellitus | 2024-03-11 | criteria provided, single submitter | clinical testing | |
Genomics England Pilot Project, |
RCV000169506 | SCV001760266 | likely pathogenic | Hyperinsulinemic hypoglycemia, familial, 1 | no assertion criteria provided | clinical testing |